Weekly epirubicin in the treatment of gestational breast cancer (GBC)

Breast Cancer Research and Treatment
Fedro A PeccatoriAron Goldhirsch

Abstract

GBC is a rare disease and chemotherapy in this setting lacks a standardized approach. Patients 16-30 weeks pregnant with locally advanced/metastatic disease or with high risk of recurrence after surgery were evaluated. Twenty patients received weekly epirubicin 35 mg/m(2). Median maternal age was 37 years (23-42). Median gestational age at chemotherapy was 19 weeks. Thirteen patients were treated after surgery while 7 had locally advanced tumours of which one had liver metastases. Mean total epirubicin dose was 420 mg/m(2) with a median number of 12 administrations (4-16). No grade 3-4 toxicities were observed. No foetal adverse events were observed except 1 premature delivery at 28 weeks. Births were induced by caesarean section in 12 patients at a median gestational age of 35 weeks. No malformations were reported except 1 newborn with polycystic kidney. At a median age of 2 years, neurological, cardiological and immunological development was normal in all children as reported by their parents. In 7/20 patients with evaluable disease, five had an objective response. At a median follow-up of 38 months, 17 patients are alive; 14 are disease free. Weekly epirubicin appears safe and effective with low foetal toxicity and could be ...Continue Reading

References

Mar 8, 1990·The New England Journal of Medicine·G S BerkowitzR L Berkowitz
Dec 1, 1989·British Journal of Cancer·C J TwelvesR D Rubens
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·C M CamaggiF Pannuti
Aug 15, 1984·International Journal of Cancer. Journal International Du Cancer·J F Haas
Jan 1, 1980·Gynecologic and Obstetric Investigation·J Kushari, M Mukherjea
May 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G BonadonnaP Valagussa
May 4, 2004·The Lancet Oncology·Elyce Cardonick, Audrey Iacobucci
Jul 3, 2004·The Lancet Oncology·Fedro PeccatoriAron Goldhirsch
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Mar 24, 2005·Journal of the National Cancer Institute. Monographs·Karin Gwyn
Jun 11, 2005·BMJ : British Medical Journal·Ludger BarthelmesChristopher A Gateley
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alistair E RingPaul A Ellis
Aug 18, 2005·American Journal of Surgery·Raanan Cohen-KeremGideon Koren
Nov 8, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AvilésM J Nambo
Aug 7, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN 10th St. Gallen conference
Sep 4, 2007·Trends in Endocrinology and Metabolism : TEM·Carmen ClappGonzalo Martínez de la Escalera
Dec 18, 2007·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·R OrecchiaG Tosi

❮ Previous
Next ❯

Citations

Feb 14, 2012·Lancet·Frédéric AmantKristel Van Calsteren
Aug 10, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E CardonickR Somer
Jul 3, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F A PeccatoriUNKNOWN ESMO Guidelines Working Group
Jul 27, 2011·Therapeutic Advances in Medical Oncology·Sophie E McGrath, Alistair Ring
Jun 30, 2015·Expert Opinion on Drug Safety·Matteo LambertiniHatem A Azim
Jul 8, 2011·Surgical Oncology·E VoulgarisN Pavlidis
Oct 12, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Frédéric AmantAndreas Du Bois
Nov 10, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hatem A AzimNicholas Pavlidis
Jul 23, 2013·The Breast : Official Journal of the European Society of Mastology·Visnu LohsiriwatOreste Gentilini
Nov 30, 2010·The Breast : Official Journal of the European Society of Mastology·H A AzimF A Peccatori
Mar 22, 2015·Cancer Treatment Reviews·Matteo LambertiniHatem A Azim
Oct 2, 2012·Clinical Journal of Oncology Nursing·Kathy L Czaplicki
Sep 20, 2016·European Journal of Cancer Care·S GarofaloA Lanzone
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hatem A Azim, Fedro A Peccatori
Sep 10, 2010·Reproductive Sciences·Kristel Van CalsterenFrédéric Amant
Feb 25, 2017·The Oncologist·Shlomit Strulov ShacharCarey K Anders
Oct 28, 2011·Clinical Obstetrics and Gynecology·Srividya Viswanathan, Bhuvaneswari Ramaswamy
Oct 28, 2011·Clinical Obstetrics and Gynecology·Carl H BackesLeif D Nelin
Jan 11, 2013·International Journal of Immunopathology and Pharmacology·L Del PupM Berretta
Nov 16, 2016·ESMO Open·Flora ZagouriMeletios-Athanassios Dimopoulos
Aug 12, 2020·Clinical Breast Cancer·Ida ParisGiovanni Scambia
Dec 9, 2020·Cancers·Francesca PoggioMatteo Lambertini
Dec 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E CardonickR Somer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.